Category - Markets

Markets

WB starts Larimar Therapeutics at OP; fair value estimate $29

William Blair initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with an “outperform” rating and fair value estimate of $29. The stock closed at $15.44 on Jan. 29. Larimar is developing intracellular-targeted...

February 1, 2021

Markets

Echelon starts Antibe Therapeutics at speculative buy; PT $15 (Canadian)

Echelon Capital Markets initiated coverage of Antibe Therapeutics (TSX:ATE) with a “speculative buy” rating and price target of $15 (Canadian). The stock was quoted at $3.70 in afternoon trading on Jan. 29. Antibe is...

January 29, 2021

Markets

AGP starts Viveve Medical at buy; PT $10.75

Alliance Global Partners launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and price target of $10.75. The stock closed at $3.55 on Jan. 28. “After two disappointing, yet entirely explainable...

January 29, 2021

Markets

Analysts offer mixed reviews of T2 Biosystems preliminary Q4 results

Analysts for BTIG, Canaccord Genuity and Alliance Global Partners had mixed reviews of preliminary fourth quarter results for T2 Biosystems (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens. Mark...

January 27, 2021

Markets

BTIG ups OncoCyte PT to $8 from $5

BTIG raised its price target for OncoCyte (NYSE American:OCX) to $8 from $5, citing a recent direct offering of $25-million with its two largest institutional shareholders, which gives the company “ammunition to execute...

January 26, 2021

Markets

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

Mackie Research Capital downgraded Cipher Pharmaceuticals (TSX:CPH) to “hold” from “buy” and reduced its price target to $1 (Canadian) from $1.50, citing marketing uncertainty, partially due to a recent unfavorable...

January 25, 2021

Markets

Mackie Research ups Aleafia Health PT to $1.50 (Canadian) from $1

Mackie Research Capital raised its price target for Aleafia Health (TSX:AH) to $1.50 (Canadian) from $1, citing an exclusive agreement with Unifor, Canada’s largest private sector union, to support medical cannabis for...

January 25, 2021

Markets

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...

January 25, 2021

Markets

Ladenburg starts Plus Therapeutics at buy; PT $8

Ladenburg Thalmann initiated coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $8. The stock closed at $2.43 on Jan. 22. The company’s lead product, rhenium nanoliposome (RNL), is a...

January 25, 2021

Markets

Raymond James ups Protech Home Medical PT to $3 (Canadian) from $2.00

Raymond James raised its price target for Protech Home Medical (TSXV:PTQ) to $3 (Canadian) from $2.00, citing an update to its valuation methodology. The stock closed at $2.05 on Jan. 21. Protech is a provider of...

January 22, 2021

Category - Markets

WB starts Larimar Therapeutics at OP; fair value estimate $29

Echelon starts Antibe Therapeutics at speculative buy; PT $15 (Canadian)

AGP starts Viveve Medical at buy; PT $10.75

Analysts offer mixed reviews of T2 Biosystems preliminary Q4 results

BTIG ups OncoCyte PT to $8 from $5

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

Mackie Research ups Aleafia Health PT to $1.50 (Canadian) from $1

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg starts Plus Therapeutics at buy; PT $8

Raymond James ups Protech Home Medical PT to $3 (Canadian) from $2.00

General

More